The Surrey Heartlands Integrated Care System Area Prescribing Committee approve the increased access to THREE switches for existing NICE approved anti-VEGF treatments to optimise response. A Diabetic Macular Oedema (DMO) treatment pathway was also agreed by the APC and is attached for information.
PLEASE NOTE: The most cost-effective anti-VEGF treatment is biosimilar ranibizumab which will be counted as a ‘free switch’ for patients where monthly injections is clinically appropriate.
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve brolucizumab as an option for treating Diabetic Macula Oedema in line with NICE TA820.
Brolucizumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians).
Primary care prescribers should be aware that their patient is receiving this medicine and ensure that this is recorded on the patient’s medication screen as a hospital-only drug in line with guidance on the PAD. This will also alert the prescriber to potential side effects and interactions with other medicines prescribed in primary care. It will also ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.
